The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Regorafenib dose optimization study (ReDOS): A phase II randomized study of lower starting dose regorafenib compared to standard dose regorafenib in patients with refractory metastatic colorectal cancer (mCRC).
 
Tanios S. Bekaii-Saab
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Genentech/Roche; Lilly; NCCN; Pfizer; Regeneron; Research to Practice; Sanofi; Sirtex Medical; Taiho Pharmaceutical
Other Relationship - Exelixis; Polaris
 
Fang-Shu Ou
No Relationships to Disclose
 
Kristen Keon Ciombor
Research Funding - Boston Biomedical; MedImmune; Pfizer
 
Mohamed I. Farhat
No Relationships to Disclose
 
Jeffrey J. Kirshner
No Relationships to Disclose
 
James A. Knost
No Relationships to Disclose
 
Daniel M. Anderson
No Relationships to Disclose
 
Gamini S. Soori
No Relationships to Disclose
 
Patrick McKay Boland
Consulting or Advisory Role - Bayer
Research Funding - Boehringer Ingelheim (Inst)
 
Donald B. Wender
No Relationships to Disclose
 
Rodwige J. Desnoyers
No Relationships to Disclose
 
Daniel J. Sargent
Consulting or Advisory Role - Abbvie; Acerta Pharma; ARIAD; Astellas Pharma; AstraZeneca/MedImmune; Biothera; Celldex; Exelixis; Genentech; Incyte; Kyowa Hakko Kirin; Medivation; Merck; Merrimack; Nektar; Novartis; Pharmacyclics; Pique; Spiration; Xbiotech
Research Funding - Celgene (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Celgene
 
Axel Grothey
Consulting or Advisory Role - Amgen (Inst); Bayer (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Lilly (Inst); Sanofi (Inst)
Research Funding - Bayer (Inst); Boston Biomedical (Inst); Eisai (Inst); Genentech/Roche (Inst); Lilly (Inst); Pfizer (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Amgen; Bayer; Boston Biomedical; Bristol-Myers Squibb; Genentech/Roche